FDA Issues Foreign Establishment R&L Final Rule, Plans U.S. Agent Database
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to unveil by year-end a database designed to help foreign device manufacturers find U.S. agents
You may also be interested in...
Regulatory News In Brief
FDA panel appointment: Aradigm VP-Clinical & Regulatory Affairs Babatunde Otulana, MD, joins Anesthesiology & Respiratory Therapy Devices Panel for a four-year, non-voting stint as its industry representative. Otulana, who joined Aradigm in 1997, previously served as a medical reviewer at the Center for Drug Evaluation & Research's pulmonary division. Aradigm's AERx pulmonary drug delivery platform recently completed Phase II studies with Novo Nordisk for an inhaled insulin formulation. A Phase III study could begin in early 2002, firm says...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.